

MACQUARIE UNIVERSITY CANCER BIOBANK

MQCB00085A REPORT

07 OCTOBER 2022


CLINICAL SUMMARY

Sex: Male
Age: 73
Pre-operative radiotherapy: No



HISTOPATHOLOGY

Specimen type: Right Hemicolectomy
Tumour site: Hepatic flexure
Tumour type: Mucinous adenocarcinoma
Tumour stage: pT3, pNo, cMo; Prognostic group Stage IIA (AJCC 8th ed.)
 MMR deficient, loss of MLH1, PMS2 nuclear expression.
 BRAFV600E positive staining



75% Tumour Content



NEXT GENERATION GENOME/TRANSCRIPTOME DATA

Provider: Australian Genome Research Facility - 150bp paired end
Data yield: Germline DNA: 349,022,952 paired end, 105.40 Gbp
 Tumour DNA: 1,017,839,493 paired end, 307.39 Gbp
 Tumour RNA: 62,597,852 paired end, 18.90 Gbp

Top pathogenic somatic mutations

Gene	Alteration	Allele Frequency	Function
ASXL1	c.1751dupG p.G585fs*12	36%	loss
BRAF	c.1799T>A p.V600E	22%	gain
BRCA1	c.1961delA p.K654fs*47	26%	loss
MSH6	C3261dupC p.F1088fs*5	38%	loss

FLOW CYTOMETRY TUMOUR DISSOCIATE ANALYSIS



Cell Type	(%) of subset
Viable cells	60.8
Viable>CD45-	47.4
Viable>CD45+	44.2
Viable>CD45+>B cells	0.76
Viable>CD45+>CD4+/Foxp3-	16.6
Viable>CD45+>Tregs+	8.4
Viable>CD45+>CD8+	10.8
Viable>CD45+>Monocytes/Macrophages	50.1